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Abstract
Background: Estimates of the prevalence of transmitted HIV drug resistance (TDR) in a population are derived
from resistance tests performed on samples from patients thought to be naïve to antiretroviral treatment (ART).
Much of the debate over reliability of estimates of the prevalence of TDR has focused on whether the sample
population is representative. However estimates of the prevalence of TDR will also be distorted if some ART-
experienced patients are misclassified as ART-naïve.
Methods: The impact of misclassification bias on the rate of TDR was examined. We developed methods to obtain
adjusted estimates of the prevalence of TDR for different misclassification rates, and conducted sensitivity analyses
of trends in the prevalence of TDR over time using data from the UK HIV Drug Resistance Database. Logistic
regression was used to examine trends in the prevalence of TDR over time.
Results: The observed rate of TDR was higher than true TDR when misclassification was present and increased as
the proportion of misclassification increased. As the number of naïve patients with a resistance test relative to the
number of experienced patients with a test increased, the difference between true and observed TDR decreased.
The observed prevalence of TDR in the UK reached a peak of 11.3% in 2002 (odds of TDR increased by 1.10 (95%
CI 1.02, 1.19, p(linear trend) = 0.02) per year 1997-2002) before decreasing to 7.0% in 2007 (odds of TDR decreased
by 0.90 (95% CI 0.87, 0.94, p(linear trend) < 0.001) per year 2002-2007. Trends in adjusted TDR were altered as the
misclassification rate increased; the significant downward trend between 2002-2007 was lost when the
misclassification increased to over 4%.
Conclusion: The effect of misclassification of ART on estimates of the prevalence of TDR may be appreciable, and
depends on the number of naïve tests relative to the number of experienced tests. Researchers can examine the
effect of ART misclassification on their estimates of the prevalence of TDR if such a bias is suspected.
Background
Estimates of the prevalence of transmitted HIV drug
resistance (TDR) in a population are derived from resis-
tance tests performed on samples from patients thought
to be naïve to antiretroviral treatment (ART). The cer-
tainty of whether a patient is naïve to treatment at the
time a sample for resistance testing is taken relies on
sources of information about a patient’s treatment sta-
tus. Patients who have moved countries or clinical
centres may not remember the exact date of starting
ART or choose not to share information about previous
therapy with their current health care provider. Poor
data collection methods and/or ways of recording data
on clinical databases may also result in incomplete or
incorrect information in an analysis, especially if data-
bases from different clinical centres need to be linked to
obtain a patient’s full treatment history.
Much of the debate over reliability of estimates of the
prevalence of TDR has focused on whether the sample
population is representative [1]. However estimates of
the prevalence of TDR will also be distorted if some
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naïve, as has been discussed with reference to UK esti-
m a t e s[ 2 , 3 ] .A sl a r g e ,m u l t i c e n t r ec o h o r ts t u d i e sa r e
increasingly utilised to assess the burden of TDR on a
national or regional level, the potential biases in such
data must be addressed.
In this paper we quantify the potential extent of this
bias and its impact on estimates of the prevalence of
TDR, illustrate methods to obtain adjusted estimates of
the prevalence of TDR under different assumptions of
the rate of misclassification, and conduct sensitivity ana-
lyses of trends in the prevalence of TDR over time using
data from the UK HIV Drug Resistance Database.
Methods
The prevalence of TDR is calculated as the proportion of
samples, from patients who are thought to be naïve to
ART, with resistance (usually defined as 1 or more major
resistance mutations from a published mutation list). In
terms of treatment misclassification, and assuming truly
ART-naïve patients are never misclassified as ART-
experienced, and that rate of resistance in experienced
patients who are misclassified as naïve is the same as the
rate of resistance in experienced patients who are not
misclassified, the observed rate of TDR is:
ObservedTDR(ˆ RN)=
REa + RNB
a + B
=
REm + RNT
m + T
(1)
where m =
a
A
is the proportion of truly experienced
patients with a resistance test misclassified as naïve (a is
the number of truly experienced patients with a resis-
tance test misclassified as naïve, A is the number of
truly experienced patients with a resistance test), T =
B
A
,
the ratio of the number of truly naïve patients with a
resistance test (B) to the number of truly experienced
patients with a resistance test, and RE (E = experienced)
and RN (N = naïve) are the rate of resistance in truly
experienced and truly naive patients with a resistance
test respectively.
To examine the effect of misclassification of treatment
status on the trend in the prevalence of TDR over time in
the UK, the first resistance test per patient conducted
whilst observed as naïve to ART (n = 18,577) and the last
test per patient conducted after being observed as treat-
ment experienced (n = 10,792) were identified from UK
HIV Drug Resistance database (to end of 2007). The mis-
classification rate, m, was chosen to be 2%, 5% or 6%.
The UK HIV Drug Resistance Database is a central repo-
sitory of genotypic resistance tests carried out as part of
routine clinical care in the United Kingdom [2]. A
patient’s observed treatment status is classified from
demographic and clinical information obtained and
linked from various sources; electronic data are provided
by the UK Collaborative HIV Cohort study (UK CHIC)
[4], the UK Register of HIV seroconverters [5], the Sur-
vey of Prevalent HIV Infections Diagnosed (SOPHID)
[6], the HIV and AIDS New Diagnoses national database
(HAP), and other hospital databases. Information on
exposure to ART is also asked for on request forms for
resistance tests, and is cross-checked with data from the
electronic databases before classifying a patient’s
observed treatment status at the time of a resistance test;
ap a t i e n t ’s observed treatment status is recorded as
unknown if there is conflicting information. The study
has UK Multicentre Ethics Committee approval (MREC/
01/2/10).
Major resistance mutations were identified using the
2009 IAS-USA guidelines [7]. Logistic regression was
used to examine trends in the prevalence of TDR over
time.
Results
Bias in the estimation of the prevalence of TDR under
different assumptions of the misclassification rate
Using equation (1) (see Methods), as expected, the
observed rate of TDR was higher than the rate of TDR in
truly naive patients (true TDR) when misclassification
was present, and increased as the proportion of misclassi-
fication increased. As the number of ART-naïve patients
with a resistance test relative to the number of ART-
experienced patients with a test increased, the difference
between the true and observed rate of TDR decreased.
Figure 1 shows the ratio of the observed rate of TDR to
the true rate for illustrative values: RE =0 . 7 ,RN =0 . 0 5o r
0.1 and m = 0.02, 0.04 or 0.06. With 6% misclassification,
at r u er a t eo fT D Ro f1 0 % ,a n d2A R T - e x p e r i e n c e d
patients with a resistance test to every 1 ART-naïve
Figure 1 The prevalence of TDR under different assumptions
of the misclassification rate. Rate of resistance in truly
experienced was 0.7. m = misclassification rate. TDR = transmitted
HIV drug resistance.
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was approximately 1.6 times the rate of true TDR. If a
lower rate of true TDR was assumed (Figure 1, RN =
0.05) or higher rate of resistance in truly experienced
patients was assumed (data not shown), the relative effect
of misclassification was more pronounced, and vice versa
if a higher rate of true TDR or lower rate of resistance in
truly experienced patients was assumed (data not shown).
Adjusted estimates of the prevalence of TDR
In practice, the misclassification rate in a surveillance
population is unknown and estimates of the prevalence
of TDR are based on patients classified as ART-naïve.
However, sensitivity analyses to obtain adjusted esti-
mates of the prevalence of TDR under different assump-
tions of the misclassification rate may be of interest. It
can be shown that adjusted TDR can be written as:
AdjustedTDR =
y − m(x + y)
Y − m(X + Y)
where Y (= B + a)a n dX (= A - a)a r et h en u m b e ro f
observed ART-naive and ART-experienced patients with
a resistance test respectively, and y (= RNB + REa) and x
(= REA - REa) are the number of observed ART-naive
and ART-experienced patients with resistance (see
Additional file 1 for derivation).
Empirical adjustment of the prevalence of TDR to account
for the effect of misclassification of treatment status: the
trend over time in the UK
The observed prevalence of TDR in the UK reached a
peak of 11.3% in 2002 (odds of TDR increased by 1.10
(95% CI 1.02, 1.19, p(linear trend) = 0.02) per year 1997-
2002) before decreasing to 7.0% in 2007 (odds of TDR
decreased by 0.90 (95% CI 0.87, 0.94, p(linear trend) <
0.001) per year 2002-2007) (Figure 2). However, trends in
adjusted estimates of the prevalence of TDR were different
as the misclassification rate increased. When the ratio of
the number of observed naïve tests to the number
observed experienced tests was high (i.e. in 1997, 2005-
2007), the effect of adjusting for misclassification was less
than for years when the ratio was low (Figure 2). Adjusted
TDR approached 0% in 1999 as the misclassification rate
increased to 6%, due to the number of misclassified
0
.
0
2
.
0
4
.
0
6
.
0
8
.
1
.
1
2
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
 
Observed TDR Adjusted TDR m = 0.02
Adjusted TDR m = 0.05 Adjusted TDR m = 0.06
Year
 
Naive tests with resistance ( x )   25        29        28        55       63       74      102     168      267     284     299 
Experienced tests with resistance ( y )   83      148       419      623     595     705     730      757     707     791     875  
Total naïve tests (Y )  320     356       398      559     634     655    1059    2094   3638   4619   4245 
Total experienced tests ( X )  113     210       554      848     803     980    1126    1190   1421   1553   1994 
Ratio of naïve to experienced tests (T)   2.8     1.7        0.7        0.7      0.8       0.7      0.9      1.8      2.6      3.0     2.1 
Figure 2 Adjusted estimates of the prevalence of TDR in the UK over time. TDR = transmitted HIV drug resistance.
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number of naïve patients with resistance.
The statistically significant upward linear trend
between 1997 and 2002 seen for the observed prevalence
of TDR was lost when the misclassification rate increased
to just under 1% (data not shown). The statistically signif-
icant downward linear trend between 2002 and 2007 was
lost when the misclassification rate increased to over 4%
(data not shown).
Discussion
We have shown that the effect of misclassification of
antiretroviral treatment status on estimates of the preva-
l e n c eo fT D Rm a yb ea p p r e c i a b l e ,e v e ni ft h er a t eo f
misclassification is low. The size of the effect depends
on the number of naïve tests relative to the number of
experienced tests, as well as the rate of resistance in
naïve and experienced patients. If in a population resis-
tance tests are being done more frequently in treatment
naïve patients than in treatment experienced, the effect
of misclassification of experienced patients as naïve on
estimates of the prevalence of TDR will be diluted.
Estimating the misclassification rate in a population is
challenging. Knowledge of the accuracy of clinical data-
bases may suggest whether the misclassification rate in
one setting may be higher or lower than in another setting
but quantifying this difference is more difficult. When esti-
mates of the prevalence of TDR in the UK were first
obtained from the UK HIV Drug Resistance Database for
all tests conducted in the UK up to 2003 [2] an exercise
was carried out to try and verify the accuracy of the ART
data. Hospital clinical notes or the resistance test request
form (which contains information on exposure to antire-
troviral therapy) were checked on a sample of supposedly
ART-naive patients with resistant mutations against infor-
mation from the databases mentioned in the Methods.
Adjusting our findings from this exercise to account for
the number of patients without resistance who may have
been misclassified, we estimated an overall misclassifica-
tion rate of approximately 2%.
In the UK the number of naïve tests conducted has
i n c r e a s e do v e rt i m em o r es h a r p l yt h a nt h en u m b e ro f
experienced tests, despite the number of patients on
ART increasing, and as a consequence the effect of mis-
classification of treatment status on estimates of the pre-
valence of TDR in recent years was minimal. The trend
in the prevalence of TDR over time in the UK was dra-
matically altered when different rates of misclassification
were assumed and the downward trend in the preva-
lence of TDR since 2002 was lost when the misclassifi-
cation rate increased to over 4%. Whilst this implies
that trends over time in the prevalence of TDR should
be interpreted with caution, an estimated misclassifica-
tion rate of approximately 2% provides reassurance that
there has been a decline in the prevalence of TDR in
the UK. This analysis assumed that the misclassification
rate was constant over time, which may be incorrect if
there are reasons to suspect that the reliability of treat-
ment history has changed over time, for example, an
increase in patients who have migrated from other
countries and have an incomplete ART history.
Misclassification of treatment status is just one factor
which may influence estimates of TDR, others include
biased sampling [1], different definitions of transmitted
resistance [8], the study of acute infections, chronic
infections, or both [1], geographical differences [1], and
the persistence of transmitted resistance mutations [9].
Conclusion
The effect of misclassification of ART on estimates of
the prevalence of TDR may be appreciable, and depends
on the number of naïve tests relative to the number of
experienced tests. Our simple formula for calculating
adjusted prevalence of TDR allows researchers to exam-
ine the effect of ART misclassification on their estimates
of the prevalence of TDR if such a bias is suspected.
However the method presented depends on the rate of
resistance in experienced patients and not all TDR sur-
veillance studies may have this information available.
Additional material
Additional file 1: Derivation of the formula for adjusted TDR.
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